cancer drug news - Search News

Daiichi Sankyo, Merck and lung cancer

Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease progressing in a late-stage study.

MarketWatch · 1d

Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine kinase inhibitor treatment met its primary endpoint of progression-free survival.

Seeking Alpha on MSN · 1d

Merck, Daiichi post late-stage trial win for novel lung cancer therapy

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) announced Tuesday that their jointly developed lung cancer drug patritumab deruxtecan, which belongs to a new class of targeted cancer drugs called antibody-drug conjugates (ADC),

FDA expands approval of breast cancer drug Kisqali

CNBC on MSN · 15h

Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.

UPI News on MSN · 16h

FDA Expands Use of Breast Cancer Drug Kisqali

While Verzenio, a drug in the same class, has been approved to lower the risk of early breast cancer returning, it's only for people with a very high risk of recurrence. Kisqali will be available to a much broader group of patients, whose disease may not be as aggressive at the time of diagnosis, Novartis said.

NBC News on MSN · 1d

FDA expands approval of breast cancer drug Kisqali to earlier-stage patients

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.

AARP1d

Rx Drug Law Saves Some Cancer Patients More Than $7,000 in 2024

A recent survey from AARP found that roughly 40 percent of adults age 65-plus who are eligible for Medicare have either ...

Science Daily4h

Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...

Schizophrenia: the new drug set to tackle the ‘cancer of psychiatry’

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

AARP10h

Cancer Drug Savings; AARP Wisconsin Poll Shift

In today’s “AARP Minute,” how some people taking chemotherapy drugs are saving thousands of dollars, plus a new poll shows a ...

Medscape18h

Case Dismissed: No Cancer Drug Delivery to Patients' Homes

Last year, the Community Oncology Alliance sued to reverse a policy that prohibits oncology practices from mailing cancer ...

Medical Xpress on MSN1d

New research could lead to better treatment for oral cancer

Dr. Chakraborty says the research opens new possibilities for oral cancer treatment, particularly addressing drug ...

4don MSN

Pfizer: Potential cachexia cancer drug shows life-saving promise

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

FierceBiotech1d

Kairos goes public with $6M IPO to fund trials of lead cancer drug

With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results